Sarah-Blythe Ballard1, Mayuko Saito, Andrew J Mirelman, Caryn Bern, Robert H Gilman. 1. aDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA bDepartment of Virology, Tohoku University Graduate School of Medicine, Sendai, Japan cAsociación Benéfica PRISMA, Lima, Peru dCentre for Health Economics, University of York, Heslington, UK eDepartment of Epidemiology and Biostatistics, University of California, San Francisco School of Medicine, San Francisco, California, USA fLaboratorios de Investigación y Desarrollo, Universidad Peruana Cayetano Heredia, Lima, Peru.
Abstract
PURPOSE OF REVIEW: We highlight recent advances relevant to understanding norovirus infections in the tropics, both in populations living in developing settings and travelers to these regions. RECENT FINDINGS: Because of the decrease in diarrheal disease associated with the global rollout of vaccines against rotavirus, norovirus is emerging as the predominant cause of diarrhea morbidity among children in the tropics, and evidence suggests that it contributes to adult disease in endemic populations and travelers. In addition to identifying potential target populations for preventive measures, we provide an update on norovirus vaccine development and concepts related to their implementation in low-income and middle-income countries. SUMMARY: These current concepts related to norovirus-attributable disease burden, clinical significance, and economic impact can potentially be applied to tailoring efforts to prevent and mitigate the effects of this important enteropathogen.
PURPOSE OF REVIEW: We highlight recent advances relevant to understanding norovirus infections in the tropics, both in populations living in developing settings and travelers to these regions. RECENT FINDINGS: Because of the decrease in diarrheal disease associated with the global rollout of vaccines against rotavirus, norovirus is emerging as the predominant cause of diarrhea morbidity among children in the tropics, and evidence suggests that it contributes to adult disease in endemic populations and travelers. In addition to identifying potential target populations for preventive measures, we provide an update on norovirus vaccine development and concepts related to their implementation in low-income and middle-income countries. SUMMARY: These current concepts related to norovirus-attributable disease burden, clinical significance, and economic impact can potentially be applied to tailoring efforts to prevent and mitigate the effects of this important enteropathogen.
Authors: R I Cama; U D Parashar; D N Taylor; T Hickey; D Figueroa; Y R Ortega; S Romero; J Perez; C R Sterling; J R Gentsch; R H Gilman; R I Glass Journal: J Infect Dis Date: 1999-05 Impact factor: 5.226
Authors: K C Hyams; A L Bourgeois; B R Merrell; P Rozmajzl; J Escamilla; S A Thornton; G M Wasserman; A Burke; P Echeverria; K Y Green Journal: N Engl J Med Date: 1991-11-14 Impact factor: 91.245
Authors: Aaron Tallant; Chad K Porter; Shannon D Putnam; David R Tribble; Tomoko I Hooper; Mark S Riddle Journal: Vaccine Date: 2014-07-30 Impact factor: 3.641
Authors: Mary Carol Jennings; Drake H Tilley; Sarah-Blythe Ballard; Miguel Villanueva; Fernando Maldonado Costa; Martha Lopez; Hannah E Steinberg; C Giannina Luna; Rina Meza; Maria E Silva; Robert H Gilman; Mark P Simons; Ryan C Maves; Miguel M Cabada Journal: Am J Trop Med Hyg Date: 2017-02-06 Impact factor: 2.345
Authors: Lisa Lindsay; Herbert L DuPont; Christine L Moe; Martin Alberer; Christoph Hatz; Amy E Kirby; Henry M Wu; Thomas Verstraeten; Robert Steffen Journal: BMC Infect Dis Date: 2018-12-03 Impact factor: 3.090
Authors: Sarah-Blythe Ballard; Aaron Tallant; Rosio G Guerra; Dawn Quigley; Regan Stiegmann; Andrew J Mirelman; Mark S Riddle; Robert H Gilman Journal: Vaccine Date: 2020-02-01 Impact factor: 4.169